Previous 10 | Next 10 |
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective i...
SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023. The report ca...
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, MA, on October 16, ...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here The CDC recently issued a warning that Respiratory Syncytial Virus (RSV), a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in th...
(NewsDirect) Proactive research analyst John Savin speaks to Thomas Warner after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC). The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the develop...
SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Compan...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . SARS-CoV-2 is not done yet — Although it is not grabbing as many headlines, the number of deaths are still greater than even a pandemic influenza year at last count. The virus ...
--News Direct-- By David Willey, Benzinga Read the latest report on NanoViricides here . SARS-CoV-2 is not done yet — Although it is not grabbing as many headlines, the number of deaths are still greater than even a pandemic influenza year at last count. The vir...
--News Direct-- Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides Inc (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. Savin gives an overview of what the company does...
2023-07-12 10:03:23 ET Gainers: Healthcare Triangle ( HCTI ) +183% . Recursion Pharmaceuticals ( RXRX ) +71% . Cadrenal Therapeutics ( CVKD ) +43% . Liminal BioSciences ( LMNL ) +40% . Eloxx Pharmaceuticals ( ELOX ) +29% . L...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
20.24%Change Percent:
NanoViricides Inc. Company Name:
NNVC Stock Symbol:
NYSE Market:
NanoViricides Inc. Website:
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says...
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, ...